Ariela Noy MD

05/30/2026

Attended and gave the opening Plenary at the Rome master class on idiopathic multicentric Castleman disease.

05/14/2026

I made The New York Times super doctors list again this year. Thank you to all those who supported my nomination. It’s very prestigious to be on such a short list!

05/14/2026

I made this year‘s New York Times super doctors list (again). It’s quite the honor to be on such a shortlist. Thank you to everyone who supported my nomination.

05/14/2026

An award from the Castleman Disease Collaborative Network.

02/23/2026

It’s today!!! Make a donation by April 15!!

join me to raise money for MSK rare cancers including lymphoma and CLL!
https://secure2.convio.net/mskcc/site/TR?px=1075081...
Our ride is Sunday March 8th!!!
Thank you!!!!

Support rare cancer research at Memorial Sloan Kettering Cancer Center.

12/10/2025

So great to be part of a team presenting all of this at ASH 2025!

I moderated the 626 Session on real world outcomes in aggressive B cell lymphoma and had two first author posters. Taught at the Medscape spotlight on rare disease about iMCD. Presented at international network and much more.

12/10/2025

Warrior Award for the Physician of the Year at

Castleman disease, collaborative network


Here with the leader of it all, David Fajgenbaum.

We also presented this at the meeting
Noy et al.
Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD).

And on Friday we did a Medscape on rare diseases where I taught about the management of iMCD.

12/10/2025

Just back from the American Society of Hematology.
Here is a poster I presented on plasmablastic lymphoma. The trial is now in a randomized phase. Participants all get EPOCH and half are getting daratumumab.

https://www.mskcc.org/cancer-care/clinical-trials/20-033

12/04/2025

Game changer for marginal zone lymphoma!
Congratulations to my MSK colleague M Lia Palomba and all involved!

The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell therapy in the U.S.

11/20/2025

Hot off the presses! Congratulations to Dr. Lorenzo Falchi at MSK and all the other investigators and participants and research teams!

FDA approves epcoritamab-bysp for follicular lymphoma indications